Key facts
- Novalgen’s last known valuation is $38.0M.
- It has raised $40.4M; the latest was Later Stage VC ($3.7M) in Nov 2024.
- Notable investors include Innovate UK, AlbionVC, Amit Nathwani, Convergys Capital, UCL Business — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Novalgen
- ·The full record, as it builds
Funding rounds
No funding rounds for Novalgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novalgen
Developer of comprehensive immunotherapy platform designed to make biological medicines. The company's platform develops breakthrough bispecific antibody therapies that can safely harness the immune system to fight cancer, enabling healthcare professionals to get advanced drugs to offer highly effective treatments with therapies that have the fewest possible side effects.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2018
- Employees
- 14
- Website
- novalgen.com/
- Ownership
- Privately Held (backing)
Novalgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novalgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novalgen in its N-PORT filings yet. We sweep new filings monthly.